Data from phase 1 trial of Triplex vaccine for control of cytomegalovirus published
City of Hope,, and Helocyte, a subsidiary of Fortress Biotech, announced data from the Phase 1 trial of Helocyte’s Triplex vaccine were published online this month in Blood, the journal of the American Society of Hematology. The vaccine is initially being developed for control of CMV. October 28, 2016